Barclays
IDYA icon

Barclays’s IDEAYA Biosciences IDYA Stock Holding History

Barclays’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.48M Buy
64,434
+48,150
+296% +$1.82M ﹤0.01% 2452
2026
Q2 		$607K Buy
16,284
+304
+2% +$9.31K ﹤0.01% 3106
2026
Q1 		$532K Sell
15,980
-219,892
-93% -$7.38M ﹤0.01% 3159
2025
Q4 		$8.15M Sell
235,872
-14,509
-6% -$463K ﹤0.01% 1841
2025
Q3 		$6.81M Sell
250,381
-70,785
-22% -$1.71M ﹤0.01% 1973
2025
Q2 		$6.75M Buy
321,166
+135,800
+73% +$2.61M ﹤0.01% 1861
2025
Q1 		$3.04M Sell
185,366
-13,390
-7% -$285K ﹤0.01% 2313
2024
Q4 		$5.11M Buy
198,756
+17,586
+10% +$498K ﹤0.01% 2150
2024
Q3 		$5.74M Buy
181,170
+118,438
+189% +$4.49M ﹤0.01% 1972
2024
Q2 		$2.2M Sell
62,732
-7,234
-10% -$286K ﹤0.01% 2065
2024
Q1 		$3.07M Sell
69,966
-106,474
-60% -$4.58M ﹤0.01% 2211
2023
Q4 		$6.28M Buy
176,440
+90,114
+104% +$2.69M ﹤0.01% 1906
2023
Q3 		$2.33M Buy
86,326
+13,049
+18% +$331K ﹤0.01% 1796
2023
Q2 		$1.72M Buy
73,277
+11,020
+18% +$227K ﹤0.01% 1974
2023
Q1 		$855K Sell
62,257
-32,086
-34% -$535K ﹤0.01% 2856
2022
Q4 		$1.71M Buy
94,343
+23,735
+34% +$399K ﹤0.01% 2368
2022
Q3 		$1.05M Buy
70,608
+68,244
+2,887% +$886K ﹤0.01% 2190
2022
Q2 		$33K Sell
2,364
-3,078
-57% -$34.2K ﹤0.01% 4205
2022
Q1 		$61K Sell
5,442
-34,318
-86% -$506K ﹤0.01% 4033
2021
Q4 		$940K Buy
39,760
+26,173
+193% +$608K ﹤0.01% 2871
2021
Q3 		$347K Buy
13,587
+1,540
+13% +$36K ﹤0.01% 3362
2021
Q2 		$252K Sell
12,047
-2,809
-19% -$57.7K ﹤0.01% 3440
2021
Q1 		$348K Buy
14,856
+9,616
+184% +$186K ﹤0.01% 3410
2020
Q4 		$73K Sell
5,240
-2,036
-28% -$27.6K ﹤0.01% 4256
2020
Q3 		$91K Buy
7,276
+648
+10% +$8.02K ﹤0.01% 4307
2020
Q2 		$94K Buy
+6,628
New +$52.2K ﹤0.01% 4561

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Barclays's IDYA Position: Q3 2026 in Review

Barclays increased its IDEAYA Biosciences (IDYA) stake by 296% in Q3 2026, buying an estimated $1.82M and bringing the position to 64,434 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

Barclays first reported a position in IDYA in Q2 2020 and has held it in 26 quarters since. The position peaked at $8.15M in Q4 2025. 144 funds tracked by Wall St. Rank hold IDYA as of Q3 2026.

  • Barclays held 64,434 shares of IDEAYA Biosciences worth $2.48M as of Q3 2026.
  • Barclays bought 48,150 IDEAYA Biosciences shares in Q3 2026, an estimated $1.82M.
  • IDEAYA Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2452 holding.
  • Barclays first reported a position in IDEAYA Biosciences in Q2 2020 and has held it in 26 quarters since.
  • Barclays's IDEAYA Biosciences position peaked at $8.15M in Q4 2025.
  • 144 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.